New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
06:37 EDTAKRXAkorn shares remain attractively valued, says Piper Jaffray
Piper Jaffray believes shares of Akorn remain attractively valued despite the recent strength. The firm expects gross margin expansion from recent acquisitions and keeps an Overweight rating on the stock with a $33 price target.
News For AKRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
17:51 EDTAKRXS&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices
Subscribe for More Information
17:22 EDTAKRXUnited Insurance to replace Akorn in S&P 600 as of 1/30 close
17:21 EDTAKRXAkorn to replace Protective Life in S&P 400 as of 1/30 close
Subscribe for More Information
January 26, 2015
07:05 EDTAKRXAkorn price target raised to $55 from $45 at Piper Jaffray
Piper Jaffray raised its price target for Akorn shares to $55 saying approvals of "seemingly minor" abbreviated New Drug Application opportunities, like last week's Phenylephrine Hydrochloride Ophthalmic Solution, could in the aggregate drive significant upside to consensus estimates in 2015 and beyond. Piper reiterates an Overweight rating on shares of Akorn.
January 20, 2015
08:09 EDTAKRXAkorn price target raised to $49 from $44 at Jefferies
Jefferies raised its price target for Akorn shares to $49 to reflect its FY15 estimates. The firm keeps a Buy rating on the stock.
07:11 EDTAKRXAkorn receives FDA approval for Phenylephrine Hydrochloride Ophthalmic Solution
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use